Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid-Reference-Cited by-同舟云学术

Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid

Published:2020-03 Issue:3 Volume:42 Page:311-314
ISSN:0387-7604
Container-title:Brain and Development
language:en
Short-container-title:Brain and Development

Author:

Tozawa Takenori,Kasai Takashi,Tatebe Harutsugu,Shiomi Kozue,Nishio Hisahide,Tokuda Takahiko,Chiyonobu Tomohiro

Publisher

Elsevier BV

Subject

Clinical Neurology,Developmental Neuroscience,General Medicine,Pediatrics, Perinatology, and Child Health

Reference11 articles.

1. Evidence in focus: nusinersen use in spinal muscular atrophy;Michelson;Neurology,2018

2. Spinraza (nusinersen): communicating hydrocephalus not related to meningitis or bleeding reported. 2018 July 31. Available from: https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information---spinraza-(nusinersen).pdf?sfvrsn=0.

3. Plasma neurofilament light chain: a potential prognostic biomarker of dementia in adult Down syndrome patients;Shinomoto;PLoS ONE,2019

4. Blake’s pouch cyst and Werdnig Hoffmann disease: report of a new association and review of the literature;Shohoud;Surg Neurol Int,2014

5. Blake’s pouch cyst in 13q deletion syndrome: posterior fossa malformations may occur due to disruption of multiple genes;Myers;Am J Med Genet A,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges;Clinical Chemistry and Laboratory Medicine (CCLM);2024-01-15

2. Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era;Frontiers in Neurology;2023-11-13

3. Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy;Journal of Clinical Medicine;2023-08-01

4. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment;European Journal of Paediatric Neurology;2023-01

5. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1–3 patients treated with nusinersen;CNS Neuroscience & Therapeutics;2022-12-13